<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="model is targeted by anti-polymerase drugs, including the approved drugs" exact="Sofosbuvir" post="and Ribavirin. Key findings The results suggest the effectiveness"/>
 <result pre="COVID-19 RdRp. Keywords Wuhan coronavirus COVID-19 RdRp Docking Structural bioinformatics" exact="Sofosbuvir" post="Nucleotide inhibitors 1 Introduction A new emerged human coronavirus"/>
 <result pre="by the Food and Drugs Administration (FDA), such as Sofosbuvir," exact="Ribavirin" post="against RdRp of Hepatitis C Virus (HCV). These drugs"/>
 <result pre="testing against different viruses. The half-maximal Effective Concentration (EC50) for" exact="Ribavirin" post="against COVID-19 is 109.5 μM, while its half-maximum Inhibition"/>
 <result pre="Inhibition Concentration (IC50) against Dengue virus is 8 μM [29,30]." exact="Sofosbuvir" post="show 4 μM against the Zika virus [31]. Remdesivir"/>
 <result pre="the native nucleotides GTP and UTP, from which IDX-184 and" exact="Sofosbuvir" post="are derived, are also tested against COVID-19 RdRp model."/>
 <result pre="Remdisivir, Guanosine triphosphate (GTP), Uracil triphosphate (UTP), Cinnamaldehyde, and Thymoquinone." exact="Sofosbuvir" post="is an approved drug by the Food and Drugs"/>
 <result pre="SARS HCoVs, and Zika virus RdRps (2017, [11,19,23,[51], [52], [53]])." exact="Ribavirin" post="is a broad-acting antiviral drug used to treat different"/>
 <result pre="COVID-19 RdRp, the difference is still non-significant for Ribavirin, Remdisivir," exact="Sofosbuvir" post="and its parent nucleotide, UTP. On average, 0.95 kcal/mol"/>
 <result pre="on the docking score. The number of H-bonds for IDX-184," exact="Sofosbuvir" post="and Ribavirin are 11, 7, and 13, respectively. On"/>
 <result pre="docking score. The number of H-bonds for IDX-184, Sofosbuvir and" exact="Ribavirin" post="are 11, 7, and 13, respectively. On the other"/>
 <result pre="7, and 13, respectively. On the other hand, IDX-184 and" exact="Sofosbuvir" post="both form metal interaction through the Mg+2 with D652"/>
 <result pre="stabilization of the formed complexes for IDX-184 and Sofosbuvir. Additionally," exact="Sofosbuvir" post="formed two hydrophobic interactions with Y510 and D651 of"/>
 <result pre="that established after docking the DAA drugs IDX-184, Sofosbuvir, and" exact="Ribavirin" post="against COVID-19 RdRp are presented. DAAs are in orange"/>
 <result pre="the abovementioned data, we can say that IDX-184, Sofosbuvir, and" exact="Ribavirin" post="can tightly bind to the newly emerged coronavirus RdRp"/>
 <result pre="viral eradication. Additionally, IDX-184 show more promising results then comes" exact="Sofosbuvir" post="as a potent inhibitor against the newly emerged COVID-19"/>
 <result pre="activity of the IMP dehydrogenase inhibitor VX-497: a comparison with" exact="ribavirin" post="and demonstration of antiviral additivity with alpha interferonAntimicrob. Agents"/>
 <result pre="a comparison with ribavirin and demonstration of antiviral additivity with" exact="alpha" post="interferonAntimicrob. Agents Chemother.44200085986610722482 30WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="of antiviral additivity with alpha interferonAntimicrob. Agents Chemother.44200085986610722482 30WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="structuresJournal of Molecular Biology26419961211368950272 41HooftR.W.VriendG.SanderC.AbolaE.E.Errors in protein structuresNature.38119962728692262 42ElfikyA.A.The antiviral" exact="Sofosbuvir" post="against mucormycosis: an in silico perspectiveFuture Virology02020null 43SummersK.L.MahrokA.K.DrydenM.D.StillmanM.J.Structural properties"/>
 <result pre="and multithreadingJ. Comput. Chem.31201045546119499576 46AngelaM.LamC.E.BansalS.Micolochick SteuerH.M.NiuC.ZennouV.KeilmanM.ZhuY.LanS.OttoM.J.FurmanP.A.Genotype and subtype profiling of" exact="PSI-7977" post="as a nucleotide inhibitor of hepatitis C virusAntimicrob. Agents"/>
 <result pre="PSI-7851 and its diastereoisomer PSI-7977J. Biol. Chem.2852010343373434720801890 49Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.137201713414027902933 50SacramentoC.Q.de MeloG.R.RochaN.LVBH.MesquitaM.de FreitasC.S.The clinically"/>
 <result pre="virus infectionAntivir. Res.137201713414027902933 50SacramentoC.Q.de MeloG.R.RochaN.LVBH.MesquitaM.de FreitasC.S.The clinically approved antiviral drug" exact="sofosbuvir" post="impairs Brazilian zika virus replicationSci Rep.720174092028098253 51Cretton-ScottE.PerigaudC.PeyrottesS.LickliderL.CamireM.LarssonM.588 in vitro"/>
 <result pre="diisobutyryl prodrug (R7128) are better than their parent nucleotides and" exact="ribavirin" post="in hepatitis C virus inhibition: a molecular modeling studyJ."/>
 <result pre="C virus, in healthy subjectsAntimicrob. Agents Chemother.552011768121060109 54GaneE.J.StedmanC.A.HylandR.H.DingX.SvarovskaiaE.SymondsW.T.Nucleotide polymerase inhibitor" exact="sofosbuvir" post="plus ribavirin for hepatitis CN. Engl. J. Med.3682013344423281974 55GlueP.The"/>
 <result pre="in healthy subjectsAntimicrob. Agents Chemother.552011768121060109 54GaneE.J.StedmanC.A.HylandR.H.DingX.SvarovskaiaE.SymondsW.T.Nucleotide polymerase inhibitor sofosbuvir plus" exact="ribavirin" post="for hepatitis CN. Engl. J. Med.3682013344423281974 55GlueP.The Clinical Pharmacology"/>
 <result pre="Pharmacology of Ribavirin. Seminars in Liver Disease19991724 56MannsM.P.McHutchisonJ.G.GordonS.C.RustgiV.K.ShiffmanM.ReindollarR.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
 <result pre="Disease19991724 56MannsM.P.McHutchisonJ.G.GordonS.C.RustgiV.K.ShiffmanM.ReindollarR.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
</results>
